What the research found

Researchers studying non-obese rats with insulin resistance found that omega-3 supplementation improved glucose control and reduced insulin resistance over eight weeks. The treated animals also showed lower inflammatory markers and improvements in cholesterol and triglyceride levels. The mechanism appears to involve a shift in immune cell behaviour—specifically, moving lymphocytes and related immune cells away from a pro-inflammatory state toward anti-inflammatory activity, including an increase in regulatory T cells.

This work addresses a gap in diabetes research. While obesity is the strongest known driver of type 2 diabetes, an estimated 10–20% of people with the condition are not obese, and the biological mechanisms underlying their insulin resistance may differ. The study used Goto-Kakizaki rats, an established animal model that develops insulin resistance without obesity, making them relevant to understanding this less-studied population.

Why it matters for you

If you're tracking fasting glucose, insulin levels, or HOMA-IR scores, this hints at a potential role for omega-3 supplementation beyond cardiovascular benefits—particularly if your metabolic issues emerge despite low body fat or without obvious obesity drivers. The research suggests the anti-inflammatory pathway may be relevant even when adipose tissue isn't the primary culprit.

That said, most MyKine users concerned with metabolic health will already be monitoring systemic inflammation markers (hsCRP, IL-6) alongside glucose tolerance. This finding doesn't change immediate protocol decisions, but it reinforces why fish oil (or algal omega-3 if plant-based) appears in many optimisation regimens. It also underscores that insulin resistance can develop through inflammatory pathways independent of weight gain—worth considering if your biomarkers suggest metabolic dysfunction despite good body composition.

Caveats

• Animal model only: findings are from rats, not humans; immune and metabolic responses may differ substantially
• Early-stage: no human trials reported; efficacy and optimal dosing in people remains unknown
• Dose extrapolation unclear: the rat doses used cannot be directly translated to human supplementation protocols
• Limited mechanistic detail in humans: the lymphocyte polarisation observed in rats has not been confirmed in human subjects with non-obese diabetes